Daily Bulletin

The Times Real Estate

.

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ -- Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams. The study...

Read more: Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody...

Business News

Maintaining Garden Aesthetics Year-Round: Seasonal Gardening for Killara Businesses

Seasonal gardening gives Killara businesses the chance to have beautiful outside areas all year round. Landscaping strategies are changed during the different seasons to help plants grow well in cha...

Daily Bulletin - avatar Daily Bulletin

Site Survey: The Foundation of Successful Construction Projects

A site survey (or land survey) is an essential early step in establishing the requirements for the successful execution and planning of construction and land development. It is a large-scale process...

Daily Bulletin - avatar Daily Bulletin

Why Brite Storage Tanks Are a Game-Changer for Your Beverage Production

Whether you’re brewing a refreshing pale ale or perfecting your cider, every step shapes the final product. That’s where brite storage tanks truly shine. Crafting beverages Australians love takes mor...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals